Your browser doesn't support javascript.
loading
Estimating health benefits and cost-savings for achieving the Healthy People 2020 objective of reducing invasive colorectal cancer.
Hung, Mei-Chuan; Ekwueme, Donatus U; White, Arica; Rim, Sun Hee; King, Jessica B; Wang, Jung-Der; Chang, Su-Hsin.
  • Hung MC; Division of Cancer Prevention and Control, U.S. Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee Bldg. 107, Chamblee, GA 30341, United States.
  • Ekwueme DU; Division of Cancer Prevention and Control, U.S. Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee Bldg. 107, Chamblee, GA 30341, United States. Electronic address: dce3@cdc.gov.
  • White A; Division of Cancer Prevention and Control, U.S. Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee Bldg. 107, Chamblee, GA 30341, United States.
  • Rim SH; Division of Cancer Prevention and Control, U.S. Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee Bldg. 107, Chamblee, GA 30341, United States.
  • King JB; Division of Cancer Prevention and Control, U.S. Centers for Disease Control and Prevention, 4770 Buford Highway, Chamblee Bldg. 107, Chamblee, GA 30341, United States.
  • Wang JD; Department of Public Health, National Cheng Kung University College of Medicine, Tainan 704, Taiwan.
  • Chang SH; Division of Public Health Sciences, Department of Surgery, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, United States.
Prev Med ; 106: 38-44, 2018 01.
Article en En | MEDLINE | ID: mdl-28964854
This study aims to quantify the aggregate potential life-years (LYs) saved and healthcare cost-savings if the Healthy People 2020 objective were met to reduce invasive colorectal cancer (CRC) incidence by 15%. We identified patients (n=886,380) diagnosed with invasive CRC between 2001 and 2011 from a nationally representative cancer dataset. We stratified these patients by sex, race/ethnicity, and age. Using these data and data from the 2001-2011 U.S. life tables, we estimated a survival function for each CRC group and the corresponding reference group and computed per-person LYs saved. We estimated per-person annual healthcare cost-savings using the 2008-2012 Medical Expenditure Panel Survey. We calculated aggregate LYs saved and cost-savings by multiplying the reduced number of CRC patients by the per-person LYs saved and lifetime healthcare cost-savings, respectively. We estimated an aggregate of 84,569 and 64,924 LYs saved for men and women, respectively, accounting for healthcare cost-savings of $329.3 and $294.2 million (in 2013$), respectively. Per person, we estimated 6.3 potential LYs saved related to those who developed CRC for both men and women, and healthcare cost-savings of $24,000 for men and $28,000 for women. Non-Hispanic whites and those aged 60-64 had the highest aggregate potential LYs saved and cost-savings. Achieving the HP2020 objective of reducing invasive CRC incidence by 15% by year 2020 would potentially save nearly 150,000 life-years and $624 million on healthcare costs.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Ahorro de Costo / Años de Vida Ajustados por Calidad de Vida / Programas Gente Sana Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País como asunto: America do norte Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Ahorro de Costo / Años de Vida Ajustados por Calidad de Vida / Programas Gente Sana Tipo de estudio: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged País como asunto: America do norte Idioma: En Año: 2018 Tipo del documento: Article